Investor Relations

Founded by some of the world's most renowned specialists in cancer diagnosis, treatment and research, Champions Oncology (OCTBB:CSBR) is engaged in the development of advanced technologies to enhance the personalized treatment of human cancers. Based on the proprietary Champions Personalized TumorGraft™ technology, Champions offers cancer patients and their physicians—as well as cancer researchers—powerful tools to more effectively guide cancer treatments for patients and the development of new cancer drugs.

Filing Detail for 03/14/2012:

10-Q Document Format Files:

Seq Description Document Type Size
1 FORM 10-Q v30499_10q.htm 10-Q 292669
2 EXHIBIT 31.1 v30499-ex31-1.htm EX-31.1 10260
3 EXHIBIT 31.2 v30499_ex31-2.htm EX-31.2 10560
4 EXHIBIT 32.1 v30499_ex32-1.htm_ex32-1.htm EX-32.1 4791
  Complete submission text file 0001144204-12-014815.txt   1550730

10-Q Data Files:

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT csbr-20121031.xml EX-101.INS 147878
6 XBRL TAXONOMY EXTENSION SCHEMA csbr-20121031.xsd EX-101.SCH 15898
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE csbr-20121031_cal.xml EX-101.CAL 26453
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE csbr-20121031_def.xml EX-101.DEF 53570
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE csbr-20121031_lab.xml EX-101.LAB 128339
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE csbr-20121031_pre.xml EX-101.PRE 73410

10-K Annual Report:

Seq Description Document Type Size
1 AMENDMENT TO FORM 10-K v305716_10ka.htm EX-101.INS 60492
2 EXHIBIT 10.3 v305716_ex10-3.htm EX-101.SCH 212396
3 EXHIBIT 31.1 v305716_ex31-1.htm EX-101.CAL 8353
4 EXHIBIT 31.2 v305716_ex31-2.htm EX-101.DEF 8242
5 EXHIBIT 32.1 v305716_ex32-1.htm EX-101.LAB 4417
  Complete submission text file 0001144204-12-014602.txt EX-101.PRE 295247

Please contact Susan Foreman at Champions Oncology, Inc., for investor information or to arrange to communicate with Company principals..

Susan Foreman
Champions Oncology, Inc.
E-mail: sforeman@championsoncology.com
Phone: 410.369.0365

Corporate Governance

Charters:

 

References:

  1. Hidalgo M et al. Activity of gemcitabine in direct patient derived xenografts predicts clinical outcome: validation of an in vivo model for drug development. J Clin Oncol 27:15s, 2009 (suppl; abstr 4528)
  2. Hidalgo M et al. A Pilot Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther August 2011 10:1311-1316
  3. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
  4. Champions data on file.